BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesClinical readout

SAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH).

Related news

NBIXNeurocrine Biosciences2026-10-20 12:30 EST

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease

NBIXNeurocrine Biosciences2026-10-30 12:30 EST

Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia

VKTXViking Therapeutics2026-10-14 11:05 EST

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

VKTXViking Therapeutics2026-10-06 11:05 EST

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

KTTAPasithea Therapeutics2026-09-14 11:00 EST

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

ALKSAlkermes plc2026-10-30 11:00 EST

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

TNXPTonix Pharmaceuticals2026-10-27 11:00 EST

Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

AXSMAxsome2026-08-31 11:00 EST

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

View all latest news

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

NBIXNeurocrine Biosciences2026-11-05 13:30 EST

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules

NBIXNeurocrine Biosciences2026-11-03 21:05 EST

Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress

NBIXNeurocrine Biosciences2026-11-02 21:49 EST

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-10-30 12:30 EST

Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia

NBIXNeurocrine Biosciences2026-10-26 12:30 EST

Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia

Stock data

Close
159.76 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States